N/A N=9 LGBTQ-affirmative CBT for Youth
Anxiety Disorders · Depression · LGBTQ
Primary: Client Satisfaction With Treatment — 27.13 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.
Alzheimer's Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 32; 13; 4; 4 Participants
Phase 2 N=23 Neoadjuvant Atezolizumab in Localized Bladder Cancer
Carcinoma, Transitional Cell
Primary: Mean log2 (Fold Change of CD3+ T-Cell Count/µm2) Over Time — -0.036; -0.041; 1.516 log2(fold change)
N/A N=61 Mindfulness + tDCS to Reduce Urgency Incontinence in Women
Urinary Incontinence, Urge
Primary: Feasibility of Study Procedures Measured by Percentage of Participants Starting Intervention Who Complete the Study — 100; 90.4; 100 percentage of participants who…
Phase 4 N=16 Safety and Efficacy of Intravenous OAV101 (AVXS-101) in Pediatric Patients With Spinal Muscular Atrophy (SMA) (OFELIA)
Muscular Atrophy, Spinal
Primary: Number of Participants With Treatment Emergent AEs and SAEs — 16; 11; 11; 3 Participants
Phase 2 N=305 A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12 — 29.2; 35.2; 53.3; 54.2 percentage of participants…
N/A N=45 Core Stabilization Programme on Kicking Velocity and Performance in Male Adolescent Football Players
Soccer · Core Stability · Sports Performance
Primary: Kicking Velocity Measurement — 71.89; 67.71; 81.05; 69.12 KM/H
Phase 1 N=26 A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
Healthy Participants
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of Omeprazole — 238.5; 688.8 ng*hr/mL
N/A N=76 Transarterial Chemoembolization Versus Proton Beam Radiotherapy for the Treatment of Hepatocellular Carcinoma
Carcinoma, Hepatocellular
Primary: Two Year Overall Survival — 65; 68 percentage of participants
N/A N=1,216 Role of On-site CT-derived FFR in the Management of Suspect CAD Patients
Coronary Artery Disease
Primary: Number of Participants With ICA Without Obstructive CAD or Intervention — 421; 483; 119; 223 Participants — p=0.05
Phase 2 N=64 SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
Endometrial Cancer
Primary: Objective Response Rate (ORR) — 20 Participants
Phase 2 N=124 A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin
Diffuse Large-Cell Lymphoma
Primary: Response Rate — 24; 28; 20; 22 Participants
N/A N=25 Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes
Type 1 Diabetes
Primary: Low Blood Glucose Index (LBGI) — 2.87; 3.19; 1.1; 1.70 score on a scale — p=0.733
Phase 2 N=6 Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
Classic Galactosemia
Primary: Number of Participants With Treatment-emergent Adverse Events — 1; 0; 0; 2 Participants
N/A N=270 Atrial Fibrillation Health Literacy and Information Technology Trial in Rural Pennsylvania Counties
Atrial Fibrillation · Familial Atrial Fibrillation · Arrhythmia, Cardiac
Primary: Proportion of Days Covered — .97; 0.97 Proportion of days covered — p=0.99